The genetics and biology of Irf5-mediated signaling in lupus

References

• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 2005; 5: 375–386
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Ramstedt U, Alm GV. Properties of human natural interferon-producing cells stimulated by tumor cell lines. Eur J Immunol 1983; 13: 471–476
   PubMed Web of Science ®Google Scholar
• Ronnblom L, Alm GV. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol 2002; 63: 1181–1193
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–869
   PubMed Web of Science ®Google Scholar
• Arnheiter H, Skuntz S, Noteborn M, Chang S, Meier E. Transgenic mice with intracellular immunity to influenza virus. Cell 1990; 62: 51–61
   PubMed Web of Science ®Google Scholar
• Pavlovic J, Schroder A, Blank A, Pitossi F, Staeheli P. Mx proteins: GTPases involved in the interferon-induced antiviral state. Ciba Found Symp 1993; 176: 233–243
   PubMedGoogle Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–264
   PubMed Web of Science ®Google Scholar
• Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23: 19–28
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441: 101–105
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294: 1540–1543
   PubMed Web of Science ®Google Scholar
• Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, Matsumoto M, Ohteki T, Kaisho T, Takaoka A, Akira S, Seya T, Taniguchi T. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci USA 2003; 100: 10872–10877
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006; 103: 2770–2775
   PubMed Web of Science ®Google Scholar
• Sharara AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: Possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J Exp Med 1997; 186: 1495–1502
   PubMed Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF. Cross-priming of CD8+T-cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009–1015
   PubMed Web of Science ®Google Scholar
• Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T-cells alive. J Exp Med 1999; 189: 521–530
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225–234
   PubMed Web of Science ®Google Scholar
• Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B-cell responses. Int Immunol 2002; 14: 411–419
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461–470
   PubMed Web of Science ®Google Scholar
• Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15: 431–439
   PubMedGoogle Scholar
• Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 2002; 71: 565–581
   PubMed Web of Science ®Google Scholar
• Malik AH, Lee WM. Chronic hepatitis B virus infection: Treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723–731
   PubMed Web of Science ®Google Scholar
• Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132: 296–305
   PubMedGoogle Scholar
• Nguyen MH, Wright TL. Therapeutic advances in the management of hepatitis B and hepatitis C. Curr Opin Infect Dis 2001; 14: 593–601
   PubMed Web of Science ®Google Scholar
• Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178–183
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431–1442
   PubMed Web of Science ®Google Scholar
• Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002; 107: 133–144
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Reed AM, Peterson EJ, Gaffney PM, Moser KL, Gregersen PK, Behrens TW. Gene expression profiling in human autoimmunity. Immunol Rev 2006; 210: 120–137
   PubMed Web of Science ®Google Scholar
• Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, Ronnblom L. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664–671
   PubMed Web of Science ®Google Scholar
• Kanayama Y, Kim T, Inariba H, Negoro N, Okamura M, Takeda T, Inoue T. Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 861–863
   Google Scholar
• Ronnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001; 22: 427–431
   PubMed Web of Science ®Google Scholar
• Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 2003; 15: 548–556
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, Koskenmies S, Widen E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Ronnblom L, Syvanen AC. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528–537
   PubMed Web of Science ®Google Scholar
• Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escribano MF, Argentine and Spanish Collaborative Groups, Pons-Estel B, Petri M, Daly M, Gregersen PK, Martin J, Altshuler D, Behrens TW, Alarcon-Riquelme ME. A common haplotype of interferon regulatory factor 5(IRF5) requlates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550–555
   PubMed Web of Science ®Google Scholar
• Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping determinants of human gene expression by regional and genome-wide association. Nature 2005; 437: 1365–1369
   PubMed Web of Science ®Google Scholar
• Demirci FY, Manzi S, Ramsey-Goldman R, Minster RL, Kenney M, Shaw PS, Dunlop-Thomas CM, Kao AH, Rhew E, Bontempo F, Kammerer C, Kamboh MI. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann Hum Genet 2007; 71: 308–311
   PubMed Web of Science ®Google Scholar
• Kyogoku C, Graham RR, Bauer JW, Vlasova I, Baechler EC, Koeuth T, Rodine PR, Ortmann WA, Gregersen P, Gaffney PM, Moser KL, Bohjanen P, Altshuler D, Behrens TW. Functional characterization of the systemic lupus erythematosus risk gene IRF-5. American college of rheumatology annual meeting 2006, Available from: http://wwwrheumatologyorg/
   Google Scholar
• Graham RR, Kyogoku C, Vlasova I, Davies L, Criswell L, Vyse T, Baechler E, Daly M, Moser K, Bojhanen P, Gaffney P, Altshuler D, Behrens T. Epistasis between three functional variants of IRF5 define risk and protective haplotypes for Human lupus american college of rheumatology annual meeting 2006, Available from: http://www.rheumatology.org/
   Google Scholar
• Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A, Lanchbury JS, Vyse TJ. Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 2007; 16: 579–591
   PubMedGoogle Scholar
• Kozyrev SV, Lewen S, Linga Reddy PMV, Pons-Estel B, The Argentine Collaborative Group, Witte T, The German Collaborative Group, Junker P, Laustrup H, Gutiérrez C, Suárez A, González-Escribano MF, Martín J, The Spanish Collaborative Group, Alarcón-Riquelme MA. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in SLE. Arthiritis Rheum. 2007;56:1234–1241
   Google Scholar
• Linga Reddy MVP, Velazquez-Cruz R, Baca V, Lima G, Granados J, Orozco L, Alarcón-Riquelme ME. Genetic association of IRF5 in adult and pediatric SLE patients: Higher frequencies of the risk haplotype and its homozygotes in mexican individuals as a result of admixture. Hum Genet 2007;121:721–727.
   Google Scholar
• Alarcon-Segovia D. Shared autoimmunity: The time has come. Curr Rheumatol Rep 2004; 6: 171–174
   Google Scholar
• Rueda B, Reddy MV, Gonzalez-Gay MA, Balsa A, Pascual-Salcedo D, Petersson IF, Eimon A, Paira S, Scherbarth HR, Pons-Estel BA, Gonzalez-Escribano MF, Alarcon-Riquelme ME, Martin J. Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3815–3819
   PubMedGoogle Scholar
• Garnier S, Dieude P, Michou L, Barbet S, Tan A, Lasbleiz S, Bardin T, Prum B, Cornelis F. The systemic lupus erythematosus new genetic factor IRF5 rs2004640-T allele is not linked to, nor associated with rheumatoid arthritis, in a family-based study from the French caucasian population. Ann Rheum Dis 2007; 66: 828–831
   PubMedGoogle Scholar
• Sánchez F, Linga Reddy MVP, Ståhl M, Alarcón-Riquelme ME. Interferon regulatory factor 5 (IRF5) gene variants do not associate with psoriasis in the swedish population (submitted)
   Google Scholar
• Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382–23390
   PubMed Web of Science ®Google Scholar
• Hayashida S, Yamasaki K, Asada Y, Soeda E, Niikawa N, Kishino T. Construction of a physical and transcript map flanking the imprinted MEST/PEG1 region at 7q32. Genomics 2000; 66: 221–225
   PubMedGoogle Scholar
• Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. J Biol Chem 2000; 275: 31805–31812
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63: 6424–6431
   PubMed Web of Science ®Google Scholar
• Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P, Pitha PM, Pinder K, Barnes BJ. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 2005; 280: 21078–21090
   PubMed Web of Science ®Google Scholar
• Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis. Science 1986; 234: 364–368
   PubMed Web of Science ®Google Scholar
• Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996; 21: 267–271
   PubMed Web of Science ®Google Scholar
• Khabar KSA. The AU-rich transcriptome: More than interferons and cytokines, and its role in disease. J. Interferon Cytokine Res. 2005; 25: 1–10
   PubMed Web of Science ®Google Scholar
• Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003; 546: 37–44
   PubMed Web of Science ®Google Scholar
• Jacob CO, Lee SK, Strassmann G. Mutational analysis of TNF-alpha gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 1996; 156: 3043–3050
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387–398
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002; 22: 5721–5740
   PubMed Web of Science ®Google Scholar
• Lin R, Yang L, Arguello M, Penafuerte C, Hiscott J. A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. J Biol Chem 2005; 280: 3088–3095
   PubMed Web of Science ®Google Scholar
• Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998; 18: 2986–2996
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: Activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998; 17: 1087–1095
   PubMed Web of Science ®Google Scholar
• Kumar KP, McBride KM, Weaver BK, Dingwall C, Reich NC. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Mol Cell Biol 2000; 20: 4159–4168
   PubMed Web of Science ®Google Scholar
• UniGene: An organized view of the transciptome, Available from: http://www.ncbi.nlm.nih.gov/UniGene/
   Google Scholar
• Cheng TF, Brzostek S, Ando O, Van Scoy S, Kumar KP, Reich NC. Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J Immunol 2006; 176: 7462–7470
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003; 278: 16630–16641
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1–14
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987–995
   PubMed Web of Science ®Google Scholar
• O'Neill LA. How Toll-like receptors signal: What we know and what we don't know. Curr Opin Immunol 2006; 18: 3–9
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. Toll-like receptor signaling and IRF transcription factors. IUBMB Life 2006; 58: 290–295
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006; 6: 644–658
   PubMed Web of Science ®Google Scholar
• Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243–249
   PubMed Web of Science ®Google Scholar
• Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, Matsuyama T, Taniguchi T, Honda K. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA 2005; 102: 15989–15994
   PubMed Web of Science ®Google Scholar
• Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280: 17005–17012
   PubMed Web of Science ®Google Scholar
• Izaguirre A, Barnes BJ, Amrute S, Yeow WS, Megjugorac N, Dai J, Feng D, Chung E, Pitha PM, Fitzgerald-Bocarsly P. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003; 74: 1125–1138
   PubMed Web of Science ®Google Scholar
• Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 3388–3393
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772–777
   PubMed Web of Science ®Google Scholar
• Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005; 434: 1035–1040
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004; 279: 45194–45207
   PubMed Web of Science ®Google Scholar
• Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108–115
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2006; 2: 619–626
   PubMedGoogle Scholar
• Garcia-Carrasco M, Fuentes-Alexandro S, Escarcega RO, Salgado G, Riebeling C. Cervera R pathophysiology of sjogren's syndrome. Arch Med Res 2006; 37: 921–932
   PubMed Web of Science ®Google Scholar
• Tak PP. Chemokine inhibition in inflammatory arthritis. Best Pract Res Clin Rheumatol 2006; 20: 929–939
   Google Scholar
• Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006; 20: 865–878
   PubMed Web of Science ®Google Scholar
• Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491
   PubMed Web of Science ®Google Scholar
• Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685–3692
   PubMed Web of Science ®Google Scholar
• Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2888–2897
   PubMed Web of Science ®Google Scholar
• Grondal G, Traustadottir KH, Kristjansdottir H, Lundberg I, Klareskog L, Erlendsson K, Steinsson K. Increased T-lymphocyte apoptosis/necrosis and IL-10 producing cells in patients and their spouses in Icelandic systemic lupus erythematosus multicase families. Lupus 2002; 11: 435–442
   PubMed Web of Science ®Google Scholar
• Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology (Oxford) 2005; 44: 975–982
   PubMed Web of Science ®Google Scholar
• Kaplan MJ. Apoptosis in systemic lupus erythematosus. Clin Immunol 2004; 112: 210–218
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001; 54: 211–219
   PubMed Web of Science ®Google Scholar
• Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467–4471
   PubMed Web of Science ®Google Scholar
• Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4: 1287–1292
   PubMed Web of Science ®Google Scholar
• Rovere P, Sabbadini MG, Fazzini F, Bondanza A, Zimmermann VS, Rugarli C, Manfredi AA. Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum 2000; 43: 1663–1672
   PubMed Web of Science ®Google Scholar
• Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, Aizawa S, Tokino T, Oren M, Taniguchi T. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 1996; 382: 816–818
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Lamphier MS, Tanaka N. IRF-1: The transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta 1997; 1333: M9–17
   PubMedGoogle Scholar
• Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 2000; 20: 1149–1161
   PubMed Web of Science ®Google Scholar
• Heylbroeck C, Balachandran S, Servant MJ, DeLuca C, Barber GN, Lin R, Hiscott J. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000; 74: 3781–3792
   PubMed Web of Science ®Google Scholar
• Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002; 21: 2914–2918
   PubMed Web of Science ®Google Scholar
• Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998; 18: 2986–2996
   PubMed Web of Science ®Google Scholar
• Lin R, Mamane Y, Hiscott J. Structural and functional analysis of interferon regulatory factor 3: Localization of the transactivation and autoinhibitory domains. Mol Cell Biol 1999; 19: 2465–2474
   PubMed Web of Science ®Google Scholar
• Kokkinakis DM, Liu X, Chada S, Ahmed MM, Shareef MM, Singha UK, Yang S, Luo J. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res 2004; 64: 7513–7525
   PubMed Web of Science ®Google Scholar